irway hyperresponsiveness (AHR) is a characteristic feature of asthma and is found in virtually every patient with this disease. However, there is considerable variability in the intensity of AHR in patients with asthma, and the level of AHR is variable both among patients with asthma and within individuals themselves. This level of AHR variability provides insight into mechanisms that regulate this process. For example, the degree of AHR is usually in proportion to the severity of the underlying asthma 1 ; those patients with more severe airway disease often have a greater degree of AHR ( Fig 1 ) . In addition, intercurrent provokers, such as viral-induced exacerbations, allergen exposure, and occupational exposures, can temporarily enhance the underlying AHR in individual patients. Furthermore, treatment of asthma not only can improve airfl ow limitations and reduce symptoms but also can modify underlying AHR. These observations have given insight into the factors and mechanisms that affect AHR and, in particular, the role and contribution, if any, of airway infl ammation in the variety of processes that determine and possibly direct AHR.
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To more fully appreciate the role of infl ammation in AHR, it is helpful to identify the components that likely make up AHR, review studies that have used either therapeutic interventions or provocative models to modify AHR, and, from these observations, attempt to gain a more comprehensive view of the complexity of processes, including infl ammation, that ultimately determine AHR.
What Are the Components of AHR?
In studying, discussing, and understanding the components that comprise AHR, it is helpful, and Airway hyperresponsiveness (AHR) is a clinical feature of asthma and is often in proportion to the underlying severity of the disease. To understand AHR and the mechanisms that contribute to these processes, it is helpful to divide the airway components that affect this feature of asthma into "persistent" and "variable" categories. The persistent component of AHR represents structural changes in the airway, whereas the variable feature relates to infl ammatory events. Insight into how these interrelated components of AHR can contribute to asthma is gained by studying treatment effects and models of asthma provocation.
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are variable and infl uenced by numerous environmental events (ie, allergens, respiratory infections, and treatment).
In arbitrarily dividing the components of AHR into these two principal components, it is understood that these processes are interrelated and likely interdependent. For example, it is presumed that if infl ammation is longstanding, the cellular components of the underlying injury become important in and to the development of structural changes in the airway and, thus, further the persistent aspect of AHR. In addition, compartmentalizing the study of AHR into these two arbitrary aspects can be insightful, although perhaps artifi cial, in dissecting the complexity of this feature of asthma. In the end, the level of AHR represents both collective and synergistic events in the airway and is the result of multiple processes, each with a unique contribution, but not in isolation from other events. The concept of variable and persistent components has undergone revisions. At present, factors altering airway structure appear most related to AHR.
Detection of AHR
It is important to indicate that detection of AHR can also be arbitrarily divided into two stimuli: direct and indirect ( Fig 4 ) . Direct stimulation of the airway to measure AHR is seen principally with methacholine or histamine, both of which act directly on airway smooth muscle to evoke a contractual response. [1] [2] [3] Because the degree of the airway contractual, or closure, response is enhanced in asthma, smaller concentrations of agonists are needed to decrease the FEV 1 by 20% and thus lead to a lower provocative concentration, causing a 20% fall in FEV 1 (PC 20 ) value. 2 In general, it has been suggested that the actions of methacholine and histamine refl ect an effect usually associated with, or attributed to, persistent changes possibly informative, to divide the factors that contribute to AHR into two categories: persistent and variable 2, 3 ( Fig 2 ) . Under this concept, which may be an oversimplifi cation of this feature of asthma, the persistent aspects of AHR have been largely attributed to structural changes in the airway, which can include subendothelial thickening, subbasement membrane thickening, smooth muscle hypertrophy, matrix deposition, and altered vascular components ( Fig 3 ) . These structural changes are often part of the histopathology found in asthma, particularly in those patients with more severe or longstanding disease; these structural changes alter the architecture of the airways to make them thicker, less compliant, and more narrowed, all features associated with a greater degree of constriction and closure when stimulated by contractile substances. The other component of AHR, the variable aspect, is believed to relate to infl ammatory events in the airway, which standing their mechanisms of effect, it is becoming possible to more comprehensively explain altered airway function in asthma and to ascertain how these alterations occur. From this approach will come a greater understanding of asthma mechanisms and eventually treatment.
What Lessons Have Been Learned About
AHR From Treatment of Asthma?
In 1999, Sont and colleagues 4 reported on the effects of a treatment strategy directed toward reducing AHR vs guideline-directed care alone on clinical outcomes of asthma and also the underlying features of airway infl ammation and histopathology in these patients. All enrolled subjects had AHR as defi ned by a PC 20 to methacholine , 8 mg/mL. The enrolled patients were divided into two groups: reference treatment (the level of step care was based on guideline recommendations) and an AHR strategy whereby the treatment dose of inhaled corticosteroids (ICS) was adjusted in an attempt to reduce the underlying AHR. The patients enrolled in both treatment arms underwent bronchoscopy with mucosal biopsy at the beginning and completion of the study; the mucosal biopsies were analyzed for infl ammation (primarily, eosinophils) and airway wall thickness.
At the completion of the study, the patients in the AHR strategy arm required a larger dose of methacholine to cause a 20% fall in FEV 1 , probably refl ecting the higher dose of ICS given to this group. In addition, those receiving ICS treatment directed by reducing the AHR had a greater improvement in their FEV 1 over the 2 years of study. Furthermore, the frequency of mild asthma exacerbations was reduced in the AHR treatment strategy group. Finally, the bronchial mucosal biopsies were analyzed, and the degree of infl ammation (ie, eosinophilia) and thickness of the airway were determined. Those patients randomized to the reference group had no change in the airway thickness over the 2 years of treatment ( Fig 5 ) . In contrast, subjects in the AHR strategy group had an approximate 40% reduction in airway thickness (reticular layer thickness). Eosinophil numbers in the biopsy specimens also tended to decrease, and interestingly, when the authors evaluated the change in mucosal eosinophilia in relationship to the improvement in methacholine PC 20 , an inverse statistical correlation emerged: the greater the decrease in eosinophils in the airway, the greater the improvement in methacholine sensitivity ( Fig 6 ) .
The authors made a number of conclusions from their observations that are relevant to the discussion of AHR. First, antiinfl ammatory therapy directed toward reducing AHR can improve lung function. in the airway. This is likely an oversimplifi cation of the interplay between structural and infl ammatory events but enables a partial dissection of some of the factors that contribute to AHR.
It is also important to point out that the presumed direct stimulating factors, particularly to histamine, are not solely the result of actions on airway smooth muscle causing airway closure. Histamine can also activate sensory fi bers in the airway and, as a consequence, not only directly contract the bronchial smooth muscle but also lead to a refl ex response that can, in turn, amplify bronchospasm. The relative contribution of histamine to direct vs indirect effects is not clearly defi ned and is likely to be variable and dependent upon existing infl ammation or other factors at the time of study. This point is raised both to indicate the crossover that exists with agonists used for measures of AHR and the interweaving of infl ammatory processes and structural changes in the airway.
A variety of indirect activators of AHR are also used to detect AHR. The experience with these indirect stimulants is less than that with methacholine or histamine, but they have the potential to add information to measurements with direct agonists. The response to the inhalation of these indirect factors does not appear to occur through a direct action on smooth muscle, but rather as a consequence of existing infl ammation and either activation of these cells or as an irritant to the airway smooth muscle. Examples of indirect factors include hypertonic aerosols, such as hypertonic saline or mannitol. In addition, adenosine monophosphate acts by stimulating mast cells to release their mediators, independent of IgE. The degree to which mast cell mediators are released by adenosine monophosphate, in turn, determines the level of AHR and refl ects underlying airway infl ammation.
There are obvious strengths and limitations to each of these approaches, direct or indirect, but by applying them to the study of AHR in asthma and under- 
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To further explore the role of cellular and tissue infl ammation, Gibson and colleagues 5 enrolled 20 patients with asthma in a study. Each subject was given 2,000 m g of beclomethasone per day for 8 weeks. At the completion of this treatment phase, AHR was measured to methacholine and hypertonic saline. These determinants of AHR were followed by a collection of induced sputum. One week later, the subjects under went a bronchoscopy with lavage and mucosal biopsy to evaluate airway lumen and mucosal infl ammation. The changes in AHR were compared with the various markers of infl ammation, including airway lumen and airway wall ( Table 1 ) . Changes in AHR to methacholine, in particular, were associated with reductions in mucosal (bronchial biopsy) metachromatic cells. In contrast, associated changes in eosinophils had less effect on AHR to methacholine or mannitol.
From these observations, the authors 5 concluded that the effects of reducing cellular infl ammation on AHR were dependent upon many factors, including the cell type (ie, eosinophil vs metachromatic cell) and the location of the infl ammatory process (ie, the lumen vs airway wall). Under these experimental conditions, two major messages can be drawn: metachromatic cells and their residence in the airway wall are the dominant factors that are most likely to infl uence altered airway physiology associated with AHR. Their fi ndings also suggest that long-term treatments with effective doses of ICS are needed to bring about changes in the mucosal tissue and for these changes to translate into functional improvement in AHR. This study also underscores the strength behind combining assessments of infl ammatory cell type and their location to unravel which cell and under what conditions it affects AHR. Again, this study suggests that it is the structural status of the airway, not necessarily infl ammation, that is important to AHR.
Second, the ICS treatment that induced changes in AHR also reduced changes of airway wall remodeling (ie, reticular layer thickness) and the degree of eosinophilia. Whether the changes in airway wall thickness and fewer eosinophils are linked and/or associated with a reduction in AHR could not be determined. Nonetheless, by adjusting the treatment dose of ICS to reduce AHR, there was a diminished thickness of the airways. Because airway thickness can factor into the degree of AHR, these outcomes appear interrelated. In the schema of the introductory comments, the reduction in AHR with higher doses of ICS appears targeted to the persistent, or structural, components of AHR. This, however, still remains conjectural. These data also raise the question of how much infl ammation, refl ected by the presence of eosinophils, contributes to AHR. 10 conducted a comprehensive study that used antigen bronchoprovo cation to induce an allergic infl ammatory response and bronchoscopy with biopsy to assess the effects of allergic infl ammation on AHR. In this study, patients were seen on fi ve separate occasions ( Fig 7 ) . Patients had screening evaluations that included obtaining bronchoscopy with bronchial biopsies after spirometry and a methacholine measurement of PC 20 . An allergen challenge was then performed and followed by bronchoscopy 24 h later, as well as assessment of the effect of allergen challenge on the methacholine PC 20 . These studies were then repeated 7 days after the allergen challenge to assess the persistence of the infl ammatory reaction and to determine whether the infl ammatory changes associated with changes in AHR were in the airway lumen, bronchial mucosa infl ammation, or both.
Twenty-four hours after allergen challenge, there was, as expected, a signifi cant decrease in the FEV 1 in the majority of patients. Furthermore, AHR to methacholine increased at 24 h post allergen challenge and remained increased at 7 days ( Fig 8 ) . When cellular infl ammation was determined by BAL eosinophils, a signifi cant increase in this cell was found 24 h
The Effect of an Inhaled Allergen Bronchial Provocation on AHR Interleukin (IL)-5 is increased in lumen secretions following allergen challenge and correlates with the presence of eosinophils recruited to the lung. 6 To dissect these processes (ie, mediator vs cellular aspects), Shi and colleagues 7 had patients with asthma inhale IL-5 and evaluated its effects on AHR and recruitment of eosinophils. Twenty-four hours after inhaling IL-5, eosinophils markedly increased in the sputum and paralleled a signifi cant enhancement in responsiveness with methacholine. These effects were not seen with saline or with a solution containing endotoxin, which could be a potential contributor to and confounder of these effects, especially the heightened response to methacholine. At the time of these studies, the Shi et al data 7 strongly suggested that the generation of IL-5 and subsequent recruitment of eosinophils are major determinants of AHR. Precisely how the eosinophils contributed to AHR was not defi ned.
This concept, however, has not been substantiated by subsequent work. Leckie and colleagues, 8 for example, evaluated the effect of administering a monoclonal antibody to IL-5 (anti-IL-5) on the airway response to inhaled antigen (ie, the development of the late phase response and eosinophil subsequent recruitment). In their study, patients with immediate and late-phase reactions to inhaled antigen were given either placebo or one of two doses of anti-IL-5. Although anti-IL-5 signifi cantly reduced blood and sputum eosinophils, there was no effect on the immediate or late-phase reaction to inhaled antigen. Furthermore, there were no changes in AHR post allergen challenge; however, changes in AHR following the antigen challenge did not occur with placebo either. These studies indicate that although eosinophils parallel the development of the late-phase reaction to inhaled antigen, they do not appear causative of this event and may not contribute to an enhancement of AHR.
Further insight into how eosinophils participate in asthma and AHR are noted in a study by Haldar 
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ing the method of evaluation, the measurement itself, the timing of the readout, and the susceptibility to the infl ammatory determinant. For example, detection of airway infl ammation is facilitated by noninvasive approaches, such as analysis of induced sputum samples. These determinants measure events in the large to midsize airways. Bronchoscopy with lavage, in contrast, provides a "cleaner" sample but requires an invasive procedure, which by itself can have effects on markers of infl ammation. Both sputum and lavage samples refl ect infl ammation in the airway lumen, which may not fully refl ect the histology of the airway wall, a location that is more likely to be a determinant of AHR. Furthermore, it is also likely that the interaction of these infl ammatory cells with airway tissues determines the intensity of AHR. At present, quantifying the interactive contribution of cellular elements and resident components to the overall infl ammatory reaction is not readily available. Therefore, to identify the contributions of infl ammation to AHR, it is important to consider the many aspects of this process, including the location of the cells (ie, lumen vs bronchial wall) and cell type as well as the many mediators associated with the injury to the airway. The present data, however, suggest that it is likely that structural changes of the airway are the greater contributor to AHR than the development of infl ammation.
The structural components of the airway previously described include airway smooth muscle. There has been considerable interest in dissecting the contribution of airway remodeling and their relationship to smooth muscle and/or features of airway smooth muscle contractile responses to the presence of AHR in asthma. As noted, the measurement of AHR after allergen challenge; however, by 7 days post allergen challenge, the eosinophils in the BAL had returned to baseline levels. In contrast, when the investigators measured procollagen-expressing cells in the bronchial biopsy specimen as a marker of airway remodeling, there was an increase in this mucosal marker 7 days after allergen challenge ( Fig 9 ) . These data suggest that the changes in AHR following allergen challenge appear to be more closely associated with structural alterations than the early recruitment of luminal eosinophils and ensuing inflammation. Although eosinophils tend to parallel these responses, they did not appear to be the causative process in this response.
Assessing the contribution to airway infl ammatory events to AHR is complicated by many factors, includ- is characterized by excessive narrowing to contractile substances that cause no effect in normal subjects and a response at a smaller dose. These characteristics represent two changes: an increased sensitivity and an ability of the airway smooth muscle to narrow excessively. Some believe the response to contraction at a lower dose (ie, increased sensitivity) may represent the less signifi cant change, and it is the exaggerated airway narrowing that is more important in asthma and the resulting altered physiology. Efforts are ongoing to sort out that the contribution of airway remodeling and altered smooth muscle to AHR. Paré et al, 11 for example, present convincing evidence that airway wall remodeling is a major contributor to the excessive airway narrowing in asthma. These same investigators have pointed out that the excessive deposition of collagen and thickening of the airway wall could protect against excessive airway narrowing. 12 Thus, the balance between these changes can lead to opposite effects. In contrast, Oliver et al 13 have convincing evidence that the increased muscle mass in asthma is a dominant factor contributing to AHR. Thus, AHR remains a complex component of asthma. Although airway infl ammation is likely a contributor to symptoms and airfl ow limitations in asthma, attention has shifted to structural alteration in the airway as the dominant factor in the regulation of AHR.
Conclusions
Defi ning the contribution of airway infl ammation to AHR depends on many aspects. First, it depends on the component of AHR that is measured, persistent vs variable. Although this is an arbitrary division, it does allow for evaluation of structural changes vs the variable level (ie, inflammation). Second, the measurement of AHR is infl uenced by the methods used to detect it, whether it is methacholine causing a direct constriction of airway muscle or other substances that are indirect activators and refl ect infl ammation. Dissecting whether structural or infl ammatory changes infl uence AHR will provide greater insight into this mechanism of asthma. The emerging data suggest that it is the structural changes of the airway that contribute to AHR; included in these structural changes are those of remodeling and smooth muscle hypertrophy.
